首页> 美国卫生研究院文献>Molecular and Clinical Oncology >Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot study
【2h】

Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot study

机译:金属微腔阵列过滤器检测肺癌患者循环肿瘤细胞的初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have developed a metallic micro-cavity array filter and an automated detection system for capturing circulating tumor cells (CTCs). In this single institutional pilot study, we assessed the ability of this device to detect CTCs in patients with lung cancer at each stage. Patients diagnosed with lung cancer, undergoing planned surgery for lung cancer, or suspected of having lung cancer were recruited (40 recruited and 2 excluded). Blood samples were obtained from the patients and 3 ml whole blood was applied to the device without any preparation. The captured cells were stained to differentiate the nucleus, and determine cytokeratin and CD45 expression. Subsequently, two operators blinded to clinical information counted the number of CTCs. Sample collection was performed at the time of recruitment, before treatment and ~3 months after initial blood collection. CTC counts at recruitment were 1.4±0.4, 1.8±1.2, 1.3±0.6 and 7.4±5.1 (mean ± SE) in clinical stages I, II, III and IV, respectively. No significant difference was observed among the stages. These data indicated the ability of this device to detect CTCs at early or non-metastatic stages of lung cancer. Further research on a larger scale is needed for a more accurate assessment of the device, and research on the utility of captured cells remains a future challenge.
机译:我们已经开发出金属微腔阵列过滤器和用于捕获循环肿瘤细胞(CTC)的自动检测系统。在这项单一的机构先导研究中,我们评估了该设备在每个阶段检测肺癌患者中CTC的能力。招募了被诊断患有肺癌,计划进行肺癌手术或怀疑患有肺癌的患者(新招募了40名患者,排除了2名)。从患者获得血液样品,将3 ml全血不加任何准备就加到该设备上。将捕获的细胞染色以区分细胞核,并确定细胞角蛋白和CD45表达。随后,两名不愿了解临床信息的操作员计算了四氯化碳的数量。在募集时,治疗前和首次采血后约3个月进行样品采集。在临床I,II,III和IV期,招募时的CTC计数分别为1.4±0.4、1.8±1.2、1.3±0.6和7.4±5.1(平均值±SE)。在各阶段之间未观察到显着差异。这些数据表明该设备在肺癌的早期或非转移阶段检测CTC的能力。为了更准确地评估设备,需要进行更大规模的进一步研究,而对捕获细胞的效用的研究仍然是未来的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号